Abstract 1584P
Background
The AIO-FLOT3 Trial suggested that conversion therapy might improve outcome in pts with metastatic gastric cancer (GC). We conducted this prospective, single-arm, phase II trial to improve conversion efficacy of ICIs combined with mFLOT regimen (fluorouracil, oxaliplatin, and nab-PTX) in pts with initially unresectable locally advanced or limited metastatic GC or GEJ adenocarcinoma.
Methods
Eligible pts received Cam 200mg, oxaliplatin 85 mg/m2, nab-PTX 125 mg/m2 or with trastuzumab if Her2 positive, each was an IV followed by fluorouracil 2400 mg/m2 as a 48-h continuous iv on day 1, every 2 weeks. Pts were assessed for tumor response and surgical feasibility every 3 cycles. The primary endpoint was R0 conversion rate.
Results
35 pts were enrolled up to 04/2023. 30 pts were evaluable. The median age was 50y. Male was 76.7%. The metastatic sites included liver 50.0% (15), retroperitoneal lymph nodes (LNs) 33.0% (10), axillary and supraclavicular LNs 6.7% (2), Krukenberg 3.3% (1), adrenal gland 3.3% (1), and locally advanced unresectable 10% (3). 7(23.3%) pts had two or more unresectable lesions. 4 pts were dMMR/MSI-H and 4 were Her2 positive. ORR was 86.7% and DCR was 96.7%. 25(83.3%) pts were assessed as resectable after conversion therapy. One pt refused surgery and 2 were cCR under observation. 22 pts (73.3%) received operation with R0 resection and no perioperative mortality. With 2 cCR included, R0 conversion rate was 80.0% (24/30). 5 pts (22.7%) achieved pCR and 12(54.5%) achieved MPR. Grade 3 AEs included 2 cases of rash, 1 case of adrenal insufficiency, 1 case each of ALT, AST elevation and febrile neutropenia. 1 pt was Grade 4 Neutrophil count decreased. (Table)
Table: 1584P
Response and surgical conversion, n (%) | N=30 | |
ORR | 26 (86.7) | |
CR | 2 (6.7) | |
PR | 24 (80.0) | |
DCR | 29 (96.7) | |
SD | 3 (10.0) | |
PD | 1 (3.3) | |
R0 conversion rate | 24 (80.0) | |
Pathological response | pCR | 5/22 (22.7) |
MPR | 12/22 (54.5) | |
cCR+pCR | 7 (23.3) |
Conclusions
Cam combined with mFLOT regimen safely induced a high conversion rate, with very high R0 resection, pCR and MPR. The findings warrant further prospective investigations.
Clinical trial identification
NCT04510064.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22